Invent Medic Sweden AB appoints EMERGO by UL as its US representative in preparation for the market registration of Efemia bladder support
Invent Medic announces that the company has appointed EMERGO by UL as its US representative in FDA-related matters, including the company’s upcoming 510(k) application for Efemia bladder support.
As previously stated, Invent Medic is planning to submit a so-called 510(k) application for its product Efemia bladder support to the FDA in 2020. A 510(k) approval grants the right to market the product in the United States. This process has now taken another step forward, as Invent Medic has signed an agreement with EMERGO by UL that will act as the company’s representative during the application process.
“It is inspiring that we have now taken another step closer to the market registration and launch of Efemia in the United States, which is expected to become the second major market for the product after Europe. EMERGO by UL is a well-established firm with substantial regulatory experience in the medical technology segment,” says Invent Medic’s CEO Karin Bryder.
About Emergo by UL
EMERGO by UL is a leading regulatory consulting firm specializing in global medical device and IVD compliance. Their comprehensive solution is designed to help companies to achieve and maintain regulatory and commercial success. With a presence on six continents, they can provide real-time service and on-the-ground expertise. Learn more at EMERGObyUL.com.
This disclosure contains information that Invent Medic Sweden is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-10-2020 20:21 CET.
For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723 811 710
About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.
MedicPen AB presenterar på Stora Aktiedagen den 2/12
MedicPen kommer att presentera 17.30-18.00 på Aktiespararnas Stora Aktiedagen den 2/12. För att följa presentationen gå in på www.aktiespararna.se/tv/live. Här finns det även en möjlighet att ställa frågor i förväg. En film av presentationen kommer att finnas tillgänglig på MedicPens hemsida dagen e...
Delårsrapport Januari–September 2020
Bolagets nettoomsättning under perioden uppgick till 1 720 Tkr (0 Tkr). Resultat efter finansiella poster -3 200 Tkr (-3 285 Tkr). Resultatet per aktie blev -0,03 kr (-0,05 kr). Beställning av ett RayPilot system till LaPaz i Madrid. Leverans och installation av systemet till Salzburg. Ospeda...
Calmark signs distributor agreement in Italy
Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with P.R.I.S.M.A. Srl (Prisma) in Italy. The agreement covers Calmark's test for assessment of COVID-19 disease severity and contains a minimum contract volume of EUR 457 500. The test, "Calmark COVID-19-LDH",...
Calmark har tecknat distributörsavtal i Italien
Calmark Sweden AB meddelade idag att ett exklusivt distributörssavtal signerats med P.R.I.S.M.A. Srl (Prisma) i Italien. Avtalet omfattar Calmarks test för att bedöma sjukdomsgraden vid covid-19 och innehåller en minsta avtalsvolym på 4,6 MSEK. Testet, ”Calmark COVID19-LDH”, är under utveckling och...